Comparative Pharmacology
Head-to-head clinical analysis: METOZOLV ODT versus MEZOFY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METOZOLV ODT versus MEZOFY.
METOZOLV ODT vs MEZOFY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective 5-HT3 receptor antagonist; blocks serotonin action at vagal nerve terminals and in the chemoreceptor trigger zone, inhibiting emetic reflex.
MEZOFY is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
2.5 mg to 5 mg orally once daily, as disintegrating tablet; may increase to 10 mg if needed
MEZOFY (mexiletine) 200 mg orally every 8 hours; may increase to 300 mg every 8 hours if needed.
None Documented
None Documented
~1.5–2 hours in normal renal function; prolonged to 10–20 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life: 8-12 hours (mean 10 h); prolonged in renal impairment (up to 24 h in CrCl <30 mL/min)
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites and unchanged drug.
Renal: 60% unchanged; biliary/fecal: 25% as metabolites; 15% other
Category C
Category C
Antiemetic
Antiemetic/Antivertigo